SCHEMBL21150845

SCHEMBL21150845

O=C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn1cc(-c2cccc(NC(=O)N3CCC4(CC3)NC(=O)N(c3ccncc3)C4=O)c2)nn1)ON1C(=O)CCC1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 4/20 0.34
▸ NPY5R Q15761 1/20 0.33
▸ KDR P35968 2/20 0.33
▸ TACR1 P25103 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ HDAC3 O15379 4/20 0.31
▸ HDAC1 Q13547 4/20 0.31
▸ HDAC6 Q9UBN7 4/20 0.31
▸ HDAC2 Q92769 3/20 0.31
▸ HDAC10 Q969S8 3/20 0.31
▸ HDAC8 Q9BY41 3/20 0.31
▸ ITGB3 P05106 1/20 0.31
▸ ITGA2B P08514 1/20 0.31
▸ FABP7 O15540 1/20 0.31
▸ TEK Q02763 1/20 0.31
▸ LIMK1 P53667 1/20 0.31
▸ LIMK2 P53671 1/20 0.31
▸ TSHR P16473 1/20 0.30
▸ SIRT2 Q8IXJ6 1/20 0.30
▸ GPR142 Q7Z601 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21151259 0.92 NAMPT (0.34) NAMPTKDRTACR1HDAC3HDAC1
SCHEMBL24974528 0.92 MAPK1 (0.33) NAMPTTACR1CYP3A4HDAC1HDAC6
SCHEMBL21150848 0.92 NAMPT (0.34) NAMPTKDRTACR1HDAC3HDAC1
SCHEMBL21150858 0.91 NAMPT (0.36) NAMPTNPY5RKDRHDAC3HDAC1
SCHEMBL21151158 0.90 NAMPT (0.33) NAMPTKDRTACR1HDAC3HDAC1
SCHEMBL21151783 0.90 NAMPT (0.33) NAMPTKDRTACR1HDAC3HDAC1
SCHEMBL21151201 0.90 MCHR1 (0.38) NAMPTCYP3A4HDAC1HDAC6TSHR
SCHEMBL21152140 0.89 ENPP2 (0.35) NAMPTTACR1FABP7LIMK1LIMK2
SCHEMBL21151315 0.89 NAMPT (0.35) NAMPTNPY5RKDRTACR1HDAC3
SCHEMBL21151272 0.89 MAPK1 (0.32) NAMPTTACR1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B NAMPT 1356/4885NPY5R 2528/4885KDR 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback